Cl-4AS-1
Based on 1 Customer Validation
Cl-4AS-1, a potent steroidal androgen receptor (AR) agonist (IC50 = 12 nM), is also an inhibitor of 5α-reductase types I and II (IC50 = 6 and 10 nM, respectively).
For research use only. We do not sell to patients.
- Purity : 99.64%
- CAS No.: 188589-66-4
- Formula: C26H33ClN2O2
- Molecular Weight:441.01
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-10002
CalcitriolVDR Agonist -
HY-12111
BMS-564929Androgen Receptor Agonist -
HY-11109
ResatorvidTLR4 Inhibitor -
HY-50855
SilmitasertibCasein Kinase 2 Inhibitor -
HY-10442
3-Deazaneplanocin AEZH2 Inhibitor -
HY-14823
SobetiromeTRβ Agonist -
HY-P1439
RS 09LPS Peptide Mimic -
HY-16985
DarolutamideAndrogen Receptor Antagonist -
HY-112256
ACP-105Androgen Receptor Modulator -
HY-110353
CU-T12-9TLR1/2 Agonist -
HY-B0022
FlutamideAntiandrogen Agent -
HY-70002
EnzalutamideAndrogen Receptor Antagonist
Biological Activity
Description
IC50 & Target
IC50: 12 nM (androgen receptor); 6 nM (5α-reductase types I); 10 nM (5α-reductase types II)[1][2]
In Vitro
Cl-4AS-1 suppresses MMP-1 promoter activity in 22Rv1 human prostate cancer cells[1].
Cl-4AS-1 (10 μM) effectively promotes the AR N/C interaction, with an average maximal activity of 35.3%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ORX rats[1]
-
Dosage:10 mg/kg
-
Administration:I.s.; 7 days
-
Result:Effect of Cl-4AS-1 on prostate and seminal vesicle growth.
Chemical Information
-
CAS No. 188589-66-4
-
Appearance Solid
-
Molecular Weight 441.01
-
Formula C26H33ClN2O2
-
Color White to off-white
-
SMILES
O=C([C@H]1CC[C@]2([H])[C@]1(C)CC[C@]3([H])[C@@]4(C)C=CC(N(C)[C@]4([H])CC[C@]32[H])=O)NC5=CC=CC=C5Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 4.41 mg/mL (10.00 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Schmidt A, et al. Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J Biol Chem. 2009 Dec 25;284(52):36367-36376. [Content Brief]
[2]. Tolman RL, et al. 4-Methyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-N-aryl-carboxamides: an approach to combined androgen blockade [5alpha-reductase inhibition with androgen receptor binding in vitro]. J Steroid Biochem Mol Biol. 1997 Mar;60(5-6):303-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2675 mL | 11.3376 mL | 22.6752 mL | 56.6881 mL |
| 5 mM | 0.4535 mL | 2.2675 mL | 4.5350 mL | 11.3376 mL |
Cl-4AS-1 Related Classifications
HY-103245 Related Classifications
Powered by Bioz